Movatterモバイル変換

[0]ホーム
URL:

BE2014C068I2 - - Google Patents

Info

Publication number
BE2014C068I2
BE2014C068I2BE2014C068CBE2014C068CBE2014C068I2BE 2014C068 I2BE2014C068 I2BE 2014C068I2BE 2014C068 CBE2014C068 CBE 2014C068CBE 2014C068 CBE2014C068 CBE 2014C068CBE 2014C068 I2BE2014C068 I2BE 2014C068I2
Authority
BE
Belgium
Prior art keywords
present
immunoglobulin
humanized
human
humanized immunoglobulin
Prior art date
Application number
BE2014C068C
Other languages
French (fr)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C068(I2)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm IncfiledCriticalMillennium Pharm Inc
Publication of BE2014C068I2publicationCriticalpatent/BE2014C068I2/fr

Links

Classifications

Landscapes

Abstract

The present invention relates to humanized immunoglobulins having binding specificity for ±4²7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human ±4²7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody. The present invention further relates to a humanized immunoglobulin light chain or heavy chain, isolated nucleic acids comprising a sequence which encodes a humanized immunoglobulin or immunoglobulin chain of the present invention (e.g., a single chain antibody), constructs comprising a nucleic acid of the present invention, and host cells comprising a nucleic acid of the present invention useful in a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in diagnostic and therapeutic applications in humans, for example to control lymphocyte infiltration (including recruitment and/or accumulation) to mucosal tissue.
BE2014C068C1996-08-152014-11-12BE2014C068I2 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US08/700,737US7147851B1 (en)1996-08-151996-08-15Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication NumberPublication Date
BE2014C068I2true BE2014C068I2 (en)2017-09-22

Family

ID=24814673

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BE2014C068CBE2014C068I2 (en)1996-08-152014-11-12

Country Status (19)

CountryLink
US (3)US7147851B1 (en)
EP (2)EP0918797B2 (en)
JP (3)JP4171071B2 (en)
CN (1)CN100406562C (en)
AT (1)ATE321788T1 (en)
AU (1)AU730326C (en)
BE (1)BE2014C068I2 (en)
BR (1)BRPI9711079B1 (en)
CA (1)CA2263106C (en)
DE (1)DE69735596T3 (en)
DK (1)DK0918797T4 (en)
ES (1)ES2262186T5 (en)
IL (3)IL128052A0 (en)
LT (1)LTC0918797I2 (en)
LU (1)LU92596I2 (en)
NZ (1)NZ334226A (en)
PT (1)PT918797E (en)
SI (1)SI0918797T2 (en)
WO (1)WO1998006248A2 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7147851B1 (en)*1996-08-152006-12-12Millennium Pharmaceuticals, Inc.Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en)1997-02-212006-10-17Genentech, Inc.Antibody fragment-polymer conjugates and uses of same
US6787523B1 (en)*1997-12-022004-09-07Neuralab LimitedPrevention and treatment of amyloidogenic disease
US7790856B2 (en)1998-04-072010-09-07Janssen Alzheimer ImmunotherapyHumanized antibodies that recognize beta amyloid peptide
TWI239847B (en)1997-12-022005-09-21Elan Pharm IncN-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)1998-04-072008-02-28Guriq BasiHumanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)1997-12-022011-06-21Janssen Alzheimer ImmunotherapyPrevention and treatment of amyloidgenic disease
US7090845B2 (en)*1998-05-132006-08-15Genentech, Inc.Diagnosis and treatment of hepatic disorders
AU2011226857B2 (en)*1998-05-132013-09-19Genentech, Inc.Diagnosis and treatment of hepatic disorders
DE69929712T2 (en)*1998-11-252006-10-19The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Alpha-E-beta-7 integrin antagonists as therapeutic agents against inflammatory diseases
AU783054B2 (en)*1999-04-222005-09-22Biogen Ma Inc.Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
AU2006220426B2 (en)*2000-04-142008-10-30Genentech Inc.Method of administering an antibody
US20010046496A1 (en)*2000-04-142001-11-29Brettman Lee R.Method of administering an antibody
US7521053B2 (en)*2001-10-112009-04-21Amgen Inc.Angiopoietin-2 specific binding agents
US7658924B2 (en)*2001-10-112010-02-09Amgen Inc.Angiopoietin-2 specific binding agents
EP1461086B1 (en)*2001-12-172010-02-17University College Cardiff Consultants Ltd.Enzymatic cleavable reagents for specific delivery to disease sites
CA2473144C (en)2002-02-052013-05-28Genentech, Inc.Protein purification
MY139983A (en)2002-03-122009-11-30Janssen Alzheimer ImmunotherapHumanized antibodies that recognize beta amyloid peptide
WO2003102132A2 (en)2002-04-262003-12-11Genetech, Inc.Non-affinity purification of proteins
PL224150B1 (en)2002-05-022016-11-30Wyeth CorpComposition containing drug conjugate including the calicheamicin derivatives and the antibody, and the pharmaceutical composition containing it
GB0210121D0 (en)*2002-05-022002-06-12Celltech R&D LtdBiological products
JP2006524039A (en)*2003-01-092006-10-26マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
AU2004209981B2 (en)*2003-02-012009-02-26Janssen Sciences Ireland UcActive immunization to generate antibodies to soluble A-beta
SI3095793T1 (en)2003-07-282020-07-31Genentech, Inc.Reducing protein a leaching during protein a affinity chromatography
ES2622522T3 (en)2003-08-262017-07-06The Regents Of The University Of Colorado, A Body Corporate Inhibitors of serine protease activity and its use in methods and compositions for the treatment of bacterial infections
JP2007521248A (en)2003-12-102007-08-02ミレニアム ファーマシューティカルズ， インコーポレイテッド Humanized anti-CCR2 antibody and methods of using the antibody
TWI366570B (en)2004-01-092012-06-21PfizerAntibodies to madcam
US7655229B2 (en)2004-09-022010-02-02Chan Andrew CAnti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en)2004-09-022010-02-16Genentech, Inc.Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
CN101094868B (en)2004-09-032013-07-10健泰科生物技术公司 Humanized anti-β7 antagonists and applications thereof
JO3000B1 (en)2004-10-202016-09-05Genentech IncAntibody Formulations.
EP1838348B1 (en)2004-12-152013-06-26Janssen Alzheimer ImmunotherapyHumanized amyloid beta antibodies for use in improving cognition
MY146381A (en)*2004-12-222012-08-15Amgen IncCompositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007160A2 (en)*2005-07-112007-01-18Pfizer LimitedAnti-madcam antibodies to treat fever
WO2007007151A2 (en)*2005-07-112007-01-18Pfizer LimitedUse of anti-mad-cam antibody for the treatment of emphysema
AU2006316629A1 (en)*2005-11-172007-05-31Millennium Pharmaceuticals, Inc.Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
US8784810B2 (en)2006-04-182014-07-22Janssen Alzheimer ImmunotherapyTreatment of amyloidogenic diseases
FR2902799B1 (en)2006-06-272012-10-26Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
WO2008079302A2 (en)2006-12-212008-07-03Millipore CorporationPurification of proteins
US8569464B2 (en)2006-12-212013-10-29Emd Millipore CorporationPurification of proteins
US8362217B2 (en)2006-12-212013-01-29Emd Millipore CorporationPurification of proteins
US7947813B2 (en)2007-01-222011-05-24Genentech, Inc.Polyelectrolyte precipitation and purification of proteins
ES2707551T3 (en)*2007-03-022019-04-04Amgen Inc Methods and compositions for treating tumor diseases
EP2125892A2 (en)*2007-03-202009-12-02Millennium Pharmaceuticals, Inc.Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
US8003097B2 (en)2007-04-182011-08-23Janssen Alzheimer ImmunotherapyTreatment of cerebral amyloid angiopathy
BRPI0813645A2 (en)2007-06-252014-12-30Esbatech Alcon Biomed Res Unit METHODS FOR MODIFYING ANTIBODIES, AND MODIFIED ANTIBODIES WITH PERFECT FUNCTIONAL PROPERTIES
SI2188302T1 (en)2007-07-092018-07-31Genentech, Inc.Prevention of disulfide bond reduction during recombinant production of polypeptides
PL2182983T3 (en)*2007-07-272014-10-31Janssen Alzheimer ImmunotherapTreatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en)2007-10-172017-03-15Janssen Alzheimer ImmunotherapImmunotherapy regimes dependent on apoe status
TWI554517B (en)2007-10-302016-10-21建南德克公司Antibody purification by cation exchange chromatography
CA2711882C (en)*2008-01-112016-07-19Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteImproved humanized anti-human .alpha.9-integrin antibody
JO2913B1 (en)2008-02-202015-09-15امجين إنك,Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8999702B2 (en)2008-06-112015-04-07Emd Millipore CorporationStirred tank bioreactor
EP2321337B2 (en)2008-08-142018-10-10Genentech, Inc.Methods for removing a contaminant using protein displacement ion exchange membrane chromatography
KR20110076918A (en)2008-09-102011-07-06제넨테크, 인크. Compositions and Methods for Preventing Oxidative Degradation of Proteins
US9067981B1 (en)2008-10-302015-06-30Janssen Sciences Ireland UcHybrid amyloid-beta antibodies
US20110020327A1 (en)2008-12-162011-01-27Millipore CorporationPurification of proteins
WO2010074953A1 (en)2008-12-162010-07-01Millipore CorporationStirred tank reactor and method
WO2010099273A1 (en)2009-02-272010-09-02Genentech, Inc.Methods and compositions for protein labelling
AU2016208453B2 (en)*2009-03-202018-02-22Amgen Inc.Alpha-4-beta-7 heterodimer specific antagonist antibody
MY162752A (en)*2009-03-202017-07-14Amgen IncAlpha-4-beta-7 heterodimer specific antagonist antibody
AU2013205341B2 (en)*2009-03-202016-05-05Amgen Inc.Alpha-4-beta-7 heterodimer specific antagonist antibody
TWI529247B (en)2009-05-132016-04-11建新公司Anti-human cd52 immunoglobulins
FI2464725T4 (en)2009-08-112025-03-21Hoffmann La RocheProduction of proteins in glutamine-free cell culture media
PL2473617T3 (en)2009-09-012020-06-29F. Hoffmann-La Roche AgEnhanced protein purification through a modified protein a elution
CN104928336B (en)2009-10-262020-05-08弗·哈夫曼-拉罗切有限公司Method for producing glycosylated immunoglobulins
PL2550018T3 (en)2010-03-222019-08-30F.Hoffmann-La Roche AgCompositions and methods useful for stabilizing protein-containing formulations
CN102958538A (en)2010-05-032013-03-06弗·哈夫曼-拉罗切有限公司Compositions and methods useful for reducing the viscosity of protein-containing formulations
US8691918B2 (en)2010-05-172014-04-08Emd Millipore CorporationStimulus responsive polymers for the purification of biomolecules
KR20190067277A (en)2010-05-282019-06-14제넨테크, 인크.Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression
CA2802756C (en)2010-06-242021-05-04Genentech, Inc.Compositions and methods for stabilizing protein-containing formulations
MX2013001267A (en)2010-08-132013-04-10Genentech IncAntibodies to il-1beta and il-18, for treatment of disease.
WO2012030512A1 (en)2010-09-032012-03-08Percivia Llc.Flow-through protein purification process
KR102493433B1 (en)2011-05-022023-01-27밀레니엄 파머슈티컬스 인코퍼레이티드FORMULATION FOR ANTI-α4β7 ANTIBODY
UA116189C2 (en)2011-05-022018-02-26Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
WO2012178102A2 (en)2011-06-242012-12-27The Regents Of The Unversity Of Colorado, A Body CorporateCompositions, methods and uses for alpha-1 antitrypsin fusion molecules
SG11201403437TA (en)2011-12-222014-07-30Genentech IncIon exchange membrane chromatography
US10745468B2 (en)2011-12-222020-08-18Kota Biotherapeutics, LlcCompositions and methods for modified B cells expressing reassigned biological agents
AU2013202648B2 (en)*2012-01-102016-05-19Konkuk UniversityCompositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA034583B1 (en)*2012-01-122020-02-21Милленниум Фармасьютикалз, Инк.USES OF ANTI-α4β7 ANTIBODY
SG10201912877SA (en)2012-03-272020-02-27Genentech IncImproved harvest operations for recombinant proteins
CN103374073A (en)*2012-04-262013-10-30中国科学院上海生命科学研究院 Humanized monoclonal antibody that recognizes the activated form of integrin α4β7
HUE071647T2 (en)2012-05-182025-09-28Genentech IncHigh-concentration monoclonal antibody formulations
US9393327B2 (en)2012-12-192016-07-19Genentech, Inc.Methods and compositions for radiohalogen protein labeling
AR095199A1 (en)2013-03-152015-09-30Genzyme Corp ANTI-CD52 ANTIBODIES
PL3166401T3 (en)2014-07-092021-01-25F. Hoffmann-La Roche AgPh adjustment to improve thaw recovery of cell banks
US10532051B2 (en)2014-10-062020-01-14Chemocentryx, Inc.Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
JP2017537105A (en)2014-11-262017-12-14ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Bedolizumab for the treatment of Crohn's disease with fistula
WO2016105572A1 (en)2014-12-242016-06-30Millennium Pharmaceuticals, Inc.PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (en)2015-03-062018-01-09Millennium Pharm Inc METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS
KR20240149974A (en)*2015-08-112024-10-15고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸Antibody
EP3344278A4 (en)2015-09-042019-01-23The California Institute for Biomedical Research IMMUNOGLOBULIN-INSULIN FUSION PROTEINS
CA3048613A1 (en)2015-12-312017-07-06The Regents Of The University Of Colorado, A Body CorporateMethods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
KR102710759B1 (en)*2016-03-142024-09-25밀레니엄 파머슈티컬스 인코퍼레이티드 How to prevent graft-versus-host disease
MX2018011025A (en)*2016-03-142019-01-10Millennium Pharm IncMethods of treating or preventing graft versus host disease.
WO2017165778A1 (en)2016-03-242017-09-28Millennium Pharmaceuticals, Inc.Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en)2016-03-242017-09-28Millennium Pharmaceuticals, Inc.Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3436610A1 (en)2016-03-292019-02-06Geltor, Inc.Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
JP7162533B2 (en)2016-05-042022-10-28ミレニアム ファーマシューティカルズ， インコーポレイテッド Triple therapy for the treatment of inflammatory bowel disease
EP3469069A4 (en)*2016-06-102020-01-22Kota Biotherapeutics, LLC COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION
CA3027286A1 (en)2016-06-122017-12-21Millennium Pharmaceuticals, Inc.Method of treating inflammatory bowel disease
WO2018104893A1 (en)2016-12-062018-06-14Glaxosmithkline Intellectual Property Development LimitedAlpha4-beta7 antibodies with incrased fcrn binding and/or half-life
AU2017382281B2 (en)2016-12-222024-07-11Genentech, Inc.Methods and formulations for reducing reconstitution time of lyophilized polypeptides
WO2018200818A2 (en)2017-04-282018-11-01Millennium Pharmaceuticals, Inc.Method of treating pediatric disorders
WO2019014572A1 (en)2017-07-142019-01-17Pfizer, Inc.Antibodies to madcam
US11180541B2 (en)2017-09-282021-11-23Geltor, Inc.Recombinant collagen and elastin molecules and uses thereof
JP7419273B2 (en)2018-07-032024-01-22ブリストル－マイヤーズ スクイブ カンパニー Method of producing recombinant proteins
CN113166695A (en)2018-10-102021-07-23勃林格殷格翰国际公司 Method for membrane gas transfer in high density bioreactor cultures
JP2022510218A (en)*2018-11-302022-01-26メモリアル スローン ケタリング キャンサー センター Heterodimer tetravalent specific antibodies and their use
AR118536A1 (en)2019-04-012021-10-20Genentech Inc COMPOSITIONS AND METHODS TO STABILIZE FORMULATIONS CONTAINING PROTEIN
WO2020210440A1 (en)2019-04-122020-10-15Geltor, Inc.Recombinant elastin and production thereof
US20230096620A1 (en)*2019-04-172023-03-30Millennium Pharmaceuticals, Inc.Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
MX2021015301A (en)*2019-06-102022-02-03Takeda Pharmaceuticals Co CELL CULTURE METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ANTIBODIES.
CN114025843A (en)*2019-06-102022-02-08武田药品工业株式会社 Antibody purification method and composition thereof
WO2021021973A1 (en)2019-08-012021-02-04Bristol-Myers Squibb CompanyMethods of improving protein productivity in fed-batch cell cultures
EP4217383A1 (en)2020-09-222023-08-02Bristol-Myers Squibb CompanyMethods for producing therapeutic proteins
US20250115666A1 (en)2021-08-052025-04-10Bristol-Myers Squibb CompanyCell culture methods for producing therapeutic proteins
US20240390869A1 (en)2021-09-212024-11-28Bristol-Myers Squibb CompanyMethods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
PE20250753A1 (en)2022-06-162025-03-13Cephalon Llc ATTENUATED IL-2-ANTI-PD-1 ANTIBODY IMMUNOCONJUGATES AND THEIR USES
TW202504919A (en)2023-05-302025-02-01美商派拉岡醫療公司Α4β7 integrin antibody compositions and methods of use
WO2024252368A2 (en)2023-06-092024-12-12Takeda Pharmaceutical Company LimitedMethods and compositions for treating ulcerative colitis
WO2025137093A1 (en)2023-12-192025-06-26Cephalon LlcUses for attenuated il-2 immunoconjugates
CN117777292B (en)*2023-12-282024-10-18天津大学Anti-integrin alpha4β7Nanobody and use thereof
WO2025149974A1 (en)2024-01-112025-07-17Takeda Pharmaceutical Company LimitedCombination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en)2024-02-202025-08-28Takeda Pharmaceutical Company LimitedTherapeutic methods

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE3220049A1 (en)1982-05-271983-12-01Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen KNITTING AND SHOULDER LOCK COMBINATION FOR V-BED FLAT KNITTING MACHINES WITH SLIDING NEEDLES
GB8308235D0 (en)1983-03-251983-05-05Celltech LtdPolypeptides
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
GB8422238D0 (en)1984-09-031984-10-10Neuberger M SChimeric proteins
US4699880A (en)*1984-09-251987-10-13Immunomedics, Inc.Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en)1986-03-271986-04-30Winter G PRecombinant dna product
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en)1987-03-181998-07-29Scotgen Biopharmaceuticals, Inc.Altered antibodies
US5258498A (en)*1987-05-211993-11-02Creative Biomolecules, Inc.Polypeptide linkers for production of biosynthetic proteins
ATE114478T1 (en)1987-08-111994-12-15Univ Leland Stanford Junior PROCEDURE FOR CONTROL OF WEUKOCYTE EXTRAVASATION.
US5403919A (en)1987-08-111995-04-04Board Of Trustees Of The Leland Stanford Junior University Stanford UniversityMethod to control leukocyte extravasation
US5538724A (en)1987-08-111996-07-23The Board Of Trustees For The Leland Stanford Junior Univ.Method of control leukocyte extravasation
US5223392A (en)*1988-01-251993-06-29Exocell, Inc.Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en)1988-02-051989-08-10Morrison Sherie LDomain-modified constant region antibodies
EP0462111A4 (en)1988-12-231992-07-08The Board Of Trustees Of The Leland Stanford Junior UniversityHoming sequences and their uses
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
IL162181A (en)*1988-12-282006-04-10Pdl Biopharma IncA method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en)*1989-02-231993-07-06Genentech, Inc.Lymphocyte homing receptor/immunoglobulin fusion proteins
IL95501A (en)1989-09-011997-04-15Hutchinson Fred Cancer ResInhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en)1989-12-211990-02-28Celltech LtdHumanised antibodies
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
WO1992015683A1 (en)1991-03-061992-09-17MERCK Patent Gesellschaft mit beschränkter HaftungHumanized and chimeric monoclonal antibodies
US5665595A (en)*1991-06-071997-09-09DowelancoImmunoglobulins against insect tissue
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
GB9115364D0 (en)1991-07-161991-08-28Wellcome FoundAntibody
US5871734A (en)1992-01-131999-02-16Biogen, Inc.Treatment for asthma with VLA-4 blocking agents
JPH07506566A (en)1992-02-121995-07-20バイオゲン　インコーポレイテッド Treatment of inflammatory gastrointestinal diseases
US5932214A (en)1994-08-111999-08-03Biogen, Inc.Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994012214A1 (en)1992-12-011994-06-09Protein Design Labs, Inc.Humanized antibodies reactive with cd18
WO1994013312A1 (en)1992-12-151994-06-23The Board Of Trustees Of The Leland Stanford Junior UniversityMucosal vascular addressin, dna and expression
EP0678122B1 (en)1993-01-121999-07-28Biogen, Inc.Recombinant anti-vla4 antibody molecules
NZ262615A (en)1993-02-091996-02-27Biogen IncTreating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
JPH06303990A (en)1993-04-241994-11-01Kanebo LtdMonoclonal antibody, hybridoma capable of producing the same and production of the same antibody
JPH08511420A (en)1993-06-161996-12-03セルテック・セラピューテイクス・リミテッド Body
US5840299A (en)1994-01-251998-11-24Athena Neurosciences, Inc.Humanized antibodies against leukocyte adhesion molecule VLA-4
DE122006000043I1 (en)1994-01-252007-02-15Elan Pharm Inc Humanized antibodies to the leukocyte adhesion molecule vla-4
US6551593B1 (en)*1995-02-102003-04-22Millennium Pharmaceuticals, Inc.Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en)*1996-01-042000-03-14Leukosite, Inc.Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en)*1996-08-152006-12-12Millennium Pharmaceuticals, Inc.Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication numberPublication date
JP5166483B2 (en)2013-03-21
CA2263106C (en)2010-08-03
ES2262186T5 (en)2015-12-11
EP0918797B2 (en)2015-09-23
JP4171071B2 (en)2008-10-22
NZ334226A (en)2000-10-27
BRPI9711079B1 (en)2017-06-20
JP4578536B2 (en)2010-11-10
US20090011464A1 (en)2009-01-08
JP2001507210A (en)2001-06-05
IL128052A0 (en)1999-11-30
EP0918797B1 (en)2006-03-29
BR9711079A (en)2000-06-06
DK0918797T3 (en)2006-07-31
CN1227607A (en)1999-09-01
PT918797E (en)2006-08-31
ATE321788T1 (en)2006-04-15
LTC0918797I2 (en)2017-05-10
ES2262186T3 (en)2006-11-16
IL128052A (en)2006-08-20
AU730326B2 (en)2001-03-01
WO1998006248A2 (en)1998-02-19
EP0918797A2 (en)1999-06-02
CN100406562C (en)2008-07-30
DE69735596T3 (en)2016-02-25
BRPI9711079B8 (en)2021-05-25
CA2263106A1 (en)1998-02-19
JP2010246548A (en)2010-11-04
US20060292140A1 (en)2006-12-28
SI0918797T2 (en)2016-01-29
AU3972897A (en)1998-03-06
DE69735596D1 (en)2006-05-18
SI0918797T1 (en)2006-10-31
EP1710314A1 (en)2006-10-11
DK0918797T4 (en)2016-01-11
JP2008281562A (en)2008-11-20
DE69735596T2 (en)2006-12-21
AU730326C (en)2005-06-16
IL175570A0 (en)2006-09-05
HK1021822A1 (en)2000-07-07
US7147851B1 (en)2006-12-12
US7402410B2 (en)2008-07-22
WO1998006248A3 (en)1998-05-07
LU92596I2 (en)2015-01-12

Similar Documents

PublicationPublication DateTitle
BE2014C068I2 (en)
PT699755E (en) METHOD FOR OBTAINING MODIFIED IMMUNOGLOBULINS WITH REDUCED IMMUNOGENICITY OF VARIABLE DOMAINS OF MURIDEO ANTIBODIES COMPOSITIONS THAT CONTAIN THEM
CY1107708T1 (en) HUMAN MONOCLONAL ANTIBODIES TO EPITERNAL GROWTH FACTOR RECEPTOR
BR9507594B8 (en) Humanized scfv monoclonal antibody, recombinant nucleic acid molecule and recombinant protein.
GB2250995A (en)Multivalent antigen-binding proteins
WO1999037681A3 (en)Method for producing antibody fragments
ATE504601T1 (en) ANTI-CD3 ANTIBODIES FOR USE TO INDUCE IMMUNOSUPRESSION
EP1362868A3 (en)Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
DE69000338D1 (en) EXPRESSION SYSTEM FOR THE PRODUCTION OF CHIMERIC MONOCLONAL ANTIBODIES.
GR3020610T3 (en)Monoclonal antibodies against tumor associated antigen, their preparation and use
CA2068222A1 (en)Monoclonal antibodies
ES2121358T3 (en) HUMANIZED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-4 HUMAN.
WO1998012334A3 (en)Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
RU94045907A (en)Human hiv-antibodies or their fragments, expression casettes, host-cells, pharmaceutical composition, method of protection
[8]ページ先頭
©2009-2025 Movatter.jp